Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Siga Technologies, a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, has received the third year of grant funding for its ongoing Lassa fever antiviral research.
Subscribe to our email newsletter
This award provides an additional $3.65 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), on top of the $2.08 million in funding that Siga has already received from this grant.
Eric Rose, CEO of Siga, said: “The additional funding received from NIAID affords us the ability to continue to explore the possibilities of ST-193 as a commercialized antiviral for Lassa fever. We believe this is a much needed drug given the severity of the disease and the large number of individuals it affects each year.”